Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

84.69 +0.86 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
72 73 Next >
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Better Buy: Novo Nordisk vs. AstraZeneca
Via The Motley Fool
Is AstraZeneca Stock a Buy?
Via The Motley Fool
3 Cheap Growth Stocks to Buy in 2025
Via The Motley Fool
Deadline Alert: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
Deadline Approaching: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
AZN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
Law Offices of Frank R. Cruz Encourages AstraZeneca PLC (AZN) Investors To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
The Law Offices of Frank R. Cruz Continues Its Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
AZN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages AstraZeneca PLC (AZN) Investors to Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AstraZeneca PLC (AZN) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including clinical trials by 2025. 
Via Benzinga
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of AstraZeneca to Contact Us to Have Their Losses Evaluated Today
From Faruqi & Faruqi LLP
Via GlobeNewswire
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ASTRAZENECA SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AstraZeneca PLC - AZN
From Kahn Swick & Foti, LLC
Via Business Wire
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END 
Via FinancialNewsMedia
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
From FN Media Group LLC
Via GlobeNewswire
Why IonQ Is the Best Quantum Computing Stock to Buy Right Now
Via The Motley Fool
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
Achilles Therapeutics announces a $12M deal with AstraZeneca for TRACERx data and plans job cuts following its strategic review. 
Via Benzinga
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN
From The Rosen Law Firm, P.A.
Via Business Wire
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption - Hagens Berman
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Law Enforcement
AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.